Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Aurinia Pharmaceuticals (AUPH) PT Raised to $11 at RBC Capital
March 20, 2019 6:29 AM EDTRBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $11.00 (from $9.00) while maintaining a Outperform rating.
no surprises out of the resultsremains on track in its Ph. III lupus nephritis trialupdated model on positive IP developments for voclosporin... More